NCT07611084 Construction of a Cohort of Elderly Patients With Atrial Fibrillation in Rural China
| NCT ID | NCT07611084 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jiangsu Taizhou People's Hospital |
| Condition | Atrial Fibrillation (AF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2026-03-14 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2026-03-14 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is a common arrhythmia in aging populations and is strongly associated with an increased risk of heart failure (HF) and adverse cardiovascular outcomes. However, early detection of HF among patients with AF remain inadequate in rural settings. This study aims to screen for HF among older adults with AF in rural China and to conduct long-term follow-up in order to observe the disease progression in patients with AF. This study will recruit at least 2,500 elderly individuals aged between 65 and 80 years, with confirmed diagnoses of AF, residing in rural areas. Participants will undergo HF screening using NT-proBNP testing and echocardiographic assessment. Additionally, data will be collected on electrocardiographic signals, seismocardiography, voice, and demographic characteristics. Following data collection, participants will be followed up every three months to monitor the incidence and progression of HF as well as the occurrence of adverse cardiovascular events.
Eligibility Criteria
Inclusion Criteria: 1. Permanent residents with local household registration in rural China. 2. Aged 65-80 years. 3. Electrocardiogram confirmation of AF or possession of a diagnostic certificate for AF issued by a specialist. 4. Willing to participate in HF screening. 5. Ability to understand the study procedures and provide written informed consent. Exclusion Criteria: 1. Expected life expectancy of less than 3 months. 2. Severe renal insufficiency (Ccr \< 30ml/min) or ongoing dialysis treatment. 3. Cardiac insufficiency secondary to correctable causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease. 4. Indications for pacemaker implantation without having undergone implantation. 5. Chronic obstructive pulmonary disease complicated by type II respiratory failure. 6. Special populations, including patients with mental illnesses.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07611084 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 80 Years, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07611084 currently recruiting?
Yes, NCT07611084 is actively recruiting participants. Contact the research team at tzyyzcm@njmu.edu.cn for enrollment information.
Where is the NCT07611084 trial being conducted?
This trial is being conducted at Taizhou, China.
Who is sponsoring the NCT07611084 clinical trial?
NCT07611084 is sponsored by Jiangsu Taizhou People's Hospital. The trial plans to enroll 2,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.